14-day Premium Trial Subscription Try For FreeTry Free
NYSE:CRXM
Delisted

Taxus Cardium Pharmaceuticals Group, Inc Stock Insider Trading

$0.000001
+0 (+0%)
At Close: Nov 10, 2022
Date Action Amount Person Type
Mar 31, 2021 Buy 0 Jemapete Christopher J
Mar 17, 2021 Buy 200 000 Jemapete Christopher J Common Stock
Mar 16, 2021 Buy 300 000 Jemapete Christopher J Common Stock
Feb 26, 2021 Buy 0 Jemapete Christopher J Common Stock
Mar 23, 2015 Buy 50 000 Hutchison Murray H Warrant to purchase Common Stock
Mar 23, 2015 Buy 50 000 Leitch Andrew M Warrant to purchase Common Stock
Feb 28, 2014 Buy 50 000 Hutchison Murray H Warrant to purchase Common Stock
Feb 28, 2014 Buy 50 000 Leitch Andrew M Warrant to purchase Common Stock
Feb 28, 2014 Buy 50 000 Mulroy Dennis Warrant to purchase Common Stock
INSIDER POWER
0
Last 9 transactions
Buy: 750 000 | Sell: 0 (Shares)

Based on the 9 latest insides trades, we have calculated the insider power to be negative at a ratio of 0.000.

In total, the insiders bought 750 000 and sold 0 CRXM shares in the last 9 trades.

Click to get the best stock tips daily for free!

About Taxus Cardium Pharmaceuticals Group, Inc

Taxus Cardium Pharmaceuticals Group Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced ... CRXM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT